Skip to content
  Black Friday: 25% Off Everything · Prices Rise 1 Dec      
Free shipping on subscriptions and orders over  $50

These studies describe research findings. 

Lets talk about Resveratrol and the benefits shown in trials

35 RCTs: CRP and hs-CRP

Pooled randomized controlled trials. Across 35 RCTs, resveratrol significantly reduced hs-CRP and CRP serum levels. The effect was strongest with supplementation for 10 weeks or longer at 500 mg/day or more. Published in Phytotherapy Research.

Reference: PubMed 34472150

200 Human Studies Across 24 Health Areas

Every clinical trial using a defined dose of purified resveratrol, reviewed by the University of Leicester. Almost 200 studies over 20 years evaluated resveratrol across at least 24 indications. There are no consensus treatment regimens yet, but resveratrol is generally well-tolerated at up to 1 g/day and consistently reduces inflammatory markers and improves aspects of dysregulated metabolism. Published in International Journal of Molecular Sciences.

Reference: PubMed 38255828

17 RCTs, 736 Adults: Inflammatory Markers

Systematic review and meta-analysis of placebo-controlled RCTs. Resveratrol significantly reduced TNF-α and hs-CRP, but had no significant effect on IL-6.

Reference: PubMed 30017172

Calorie Restriction-Like Effects in 30 Days

11 healthy obese men, 150 mg/day, randomized double-blind crossover vs placebo, 30 days. In muscle, resveratrol activated AMPK, raised SIRT1 and PGC-1α levels and improved mitochondrial respiration. It also lowered liver fat, glucose, triglycerides and inflammation markers, and systolic blood pressure dropped. Maastricht University. Published in Cell Metabolism.

Reference: PMC3880862


Older Adults: Memory and Brain Connectivity

23 healthy overweight older adults completed 26 weeks of resveratrol (200 mg/day, in a formula with quercetin to increase bioavailability) and were matched to 23 placebo controls. Word retention over 30 minutes improved significantly versus placebo. Resveratrol also increased hippocampal functional connectivity and decreased HbA1c and body fat. Charité Berlin. Published in Journal of Neuroscience.

Reference: PubMed 24899709



Postmenopausal Women: 24-Month Trial

125 postmenopausal women aged 45–85 took 75 mg trans-resveratrol or placebo twice daily for 12 months, then crossed over for another 12 months. This is the largest, longest-running study of its kind with resveratrol. Low-dose resveratrol enhanced cognition, cerebrovascular function and insulin sensitivity. Women aged 65 and over showed a greater relative improvement in verbal memory. University of Newcastle (Australia). Published in Clinical Nutrition.

Reference: PubMed 32900519

11 RCTs, 388 Participants: Glucose Markers

Resveratrol significantly reduced fasting glucose, insulin, HbA1c and insulin resistance in participants with diabetes. No significant effect was found in non-diabetic participants. Published in American Journal of Clinical Nutrition.

Reference: PubMed (DOI 10.3945/ajcn.113.082024)





Where Results Were Neutral: Healthy Non-Obese Women

A 12-week randomized, double-blind, placebo-controlled trial of 75 mg/day in nonobese postmenopausal women with normal glucose tolerance. Plasma resveratrol rose, but body composition, resting metabolic rate, plasma lipids and inflammatory markers did not change. Washington University. Published in Cell Metabolism.

Reference: PubMed 23102619